GlassScriptPhysician profile
Dolly Wahid
NPI 1831395177
$903.79
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $549 · 2020: $86.13 · 2021: $123 · 2022: $146.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $297.71 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $268.27 | 2019-2021 | |
| Abbvie INC. | $125.00 | 2022 | |
| Pfizer INC. | $104.70 | 2019-2021 | |
| Melinta Therapeutics, LLC | $36.26 | 2019 | |
| Allergan, INC. | $33.73 | 2019 | |
| Alexion Pharmaceuticals, INC. | $23.92 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.20 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dolly Wahid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.